Document:

Exhibit 10.26

 

CANADA LICENSING AGREEMENT

 

This agreement (“Agreement”) is between
GLOBAL PHARMA HUB (“Sub-Licensor”), a corporation doing business at 200 South Knowles Avenue, Winter Park, FL 32789 and
SHEEN BOOM INVESTMENTS, LTD. a corporation doing business at 4703 Central Plaza, 18 Harbour Road, WanChai, Hong Kong, and JETSAW
PHARMACEUTICAL, INC. a corporation doing business at U6 Saddlemead Way, Neucalgary, Alberta, T3J 4J5, collectively known as “Sub-licensees”,
for a sub-license to market and distribute RapiMed products.

 

A description of RapiMed is as follows:

 

The target market for RapiMed is all OTC and prescription drugs,
and we anticipate great success because our of our its NEW oral delivery technology (CDT) that is more effective than existing
products due to its ability to melt faster, taste better and provide more accurate dosing.

 

Unlike other products available, ScripsAmerica's
initial pediatric remedy is much smaller and dissolves in the child's mouth in 25 seconds, therefore entering their system faster.
RapiMed for children's pain and fever relief contains Acetaminophen (main ingredient in Tylenol), however the bitter taste of this
active ingredient is masked. The cherry and wild grape flavors that our product will come in are most appealing to children. Additionally,
RapiMed for children pain and fever relief's dosage is controlled, not like the syringe based competing products and we offer the
80 mg for 2-6 year olds, and 160 mg for the 6-11 year olds.

 

RapiMed's children's pain and fever relief
packaging is convenient, portable, child resistant and easy to use as well as eye-catching. The contents are aspirin free, ibuprofen
free, sugar free and gluten free as well. Since the numerous Tylenol recalls in the recent past, there is a clear need for a better
controlled, more efficient product to fill the void. We believe our RapiMed for children's pain and fever relief is that product.

 

www.rapimeds.com

 

Trade-marks that Fall Under the License Agreement:

 

Trademark:RAPIMED

Class:005

Our ref.: 77722

 

Trademark: MELTS IN YOUR CHILD'S MOUTH

Trademark Serial Number: 85932286 

USPTO Number: 4472782

 

In consideration of the foregoing premises
and the mutual covenants set forth in this agreement and other valuable considerations, the parties agree as follows:

 

1. License: Sub-Licensor
hereby grants Sub-Licensees the Exclusive Canada Sub-License to use RapiMed Products for the permitted uses as set forth
in this agreement only. All other rights in and to the Products, including but not limited to all copyright and other intellectual
property rights relating to the Product are retained by Master Licensor, ScripsAmerica, Inc.

 

    	1

    	 

    

 

2. Permitted Uses: Sub-Licensees may only use the Product
as follows:

 

	A.		Sub-Licensees may display Product either physically or electronically;

 

	B.		Sub-Licensees may extract or use information contained in Product for educational
or research purposes, including extraction and manipulation of information for the purpose of illustration, explanation, example,
comment, criticism, teaching, research, or analysis;

 

	C.		Sub-Licensees may enter into marketing and distribution contracts with third party
companies in Canada;

 

3. Prohibited Uses: Sub-Licensees is
prohibited from the use of Product not expressly permitted in the preceding section. Prohibited uses include but are not limited
to:

 

	A.		Using any aspect of the Product as part of a trade-mark, design-mark, trade name;

 

	B.		Incorporating the Product in any way that results in a re-distribution or reuse of
the Product or is otherwise made available in a manner such that a third party can extract or access or reproduce Product;

 

	C.		Using the Product in a manner that is considered under applicable law to be infringing,
defamatory or libelous in nature, or that would be reasonably likely cause any person or property reflected in the Product to
be seen in a false light;

 

	D.		Removing any notice of copyright, trade-mark or other proprietary right from any place
where it is on or embedded in the Product;

 

	D.		Engaging in sales of Product, both physical and on-line, in the territory outside
of Canada;

 

	E.		Entering into distribution agreements with online distributors, as that right is solely
held by Sub-Licensor;

 

	F.		Sub-Licensing, gifting, assigning, transferring Product rights to any third party

 

4. Term: The grant of this sub-license
is effective as of the signing of this agreement for a period of three (3) years and shall renew automatically for additional one
(1) year periods unless terminated by one of the parties with ninety (90) days notice. The sub-license may be terminated without
notice from Sub-Licensor if at any time Sub-Licensee fails to comply with any of its terms of use as stated in this agreement.
Upon termination, Sub-Licensees must immediately cease all use of Product and if requested, confirm to Sub-Licensor in writing
compliance wills these requirements.

 

    	2

    	 

    

 

5.Minimum
Quotas: During the first 12 months after the Effective Date herein the Sub-Licensees will deliver to the Sub-Licensor a minimum
dollar value of orders in excess of $120,000 of the SubLicensor's Pediatric RapiMed product.

 

During the following 12 months after the effective
date herein the Sub-Licensees will deliver to the Sub-Licensor a minimum dollar value of orders in excess of $220,000 of the Sub-Licensor's
Pediatric RapiMed product.

 

During the following 12 months after the effective
date herein the Sub-Licensees will deliver to the Sub-Licensor a minimum dollar value of orders in excess of $320,000 of the Sub-Licensor's
Pediatric RapiMed product.

 

Failure to comply with the stated minimums shall be grounds for
termination of the Sub-License by the Sub-Licensor. Notice of termination with 10 days notice will be delivered by mail from the
Sub-Licensor to the Sub-Licensees via U S mail with a return receipt proof of delivery.

 

The quotas commence 90 days after the acceptance
of the registration (the Effective Date) in Canada of the Sub-Licensor's Pediatric RapiMed product.

 

6.Stock
Compensation: Global Pharma/Assigns and Sheen Boom/Assigns will receive 200,000 Restricted Common Shares of ScripsAmerica (OTC:
SCRC) for services rendered in establishing the RapiMed Canada marketing and distribution operation. Global Pharma will receive
its shares in the name of Sterling, LLC and Sheen Boom will receive its shares in the name of Forbes Investments, Ltd. Shares will
be dated 2/17/2014 and delivered by Federal Express to the addresses listed in the opening section of this agreement on Page 1.

 

6. Warranties: Sub-Licensor grants no
rights and makes no warranties regarding the use of names, people, trademarks, trade dress, patented or copyrighted designs or
works of art or architecture or other forms of intellectual property represented in any Product.

 

THE PRODUCT IS PROVIDED "AS IS" WITHOUT
REPRESENTATION, WARRANTY OR CONDITION OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO THE IMPLIED REPRESENTATIONS,
WARRANTIES OR CONDITIONS OF MERCHANTABILITY, OR FITNESS FOR A PARTICULAR PURPOSE. LICENSOR DOES NOT REPRESENT OR WARRANT THAT THE
PRODUCT WILL MEET SUB-LICENSEES REQUIREMENTS OR THAT ITS USE WILL BE UNINTERRUPTED OR ERROR FREE. THE ENTIRE RISK AS TO THE QUALITY
AND PERFORMANCE OF THE PRODUCT IS WITH THE MANUFACTURER AND MASTER LICENSOR. SHOULD THE PRODUCT PROVE DEFECTIVE, MANUFACTURER AND
MASTER LICENSOR ASSUMES THE ENTIRE RISK AND COST OF ALL NECESSARY CORRECTIONS.

 

7.Indemnification:
Each party shall indemnify, assume the defense of, and hold harmless the other party and its directors, officers, employees,
and agents from every claim, loss, damage, injury, expense (including attorney's fees), judgment, and liability of every kind,
nature, and description arising in whole or in part from the indemnifying party's negligent, fraudulent, or illegal acts or omissions
except, as to the party requesting indemnification, to the extent such Liability results in whole or in part from the unauthorized,
negligent, fraudulent, or illegal act or omission of the party requesting indemnification.

 

    	3

    	 

    

 

8.
Amendments to Sub-License: This sub-license may only be amended by a writing signed by Sub-Licensees and authorized
by Sub-Licensor.

 

9.
Legal Disputes: This Agreement has been negotiated and is being contracted for in the State of Florida. It shall
be governed by and interpreted in accordance with the laws of the State of Florida, regardless of any conflict-of-law provision
to the contrary. In any dispute arising out of or connected with this Agreement, each party consents to the exclusive jurisdiction
of the courts of the State of Florida or the federal district court for Florida; each Party consents to the personal jurisdiction
of such courts; and each Party waives any objection to personal jurisdiction or venue.

 

The parties waive any right to argue conflict
of law principles. The Parties agree that any claim or dispute between them or against any agent, employee, successor, or assign
of the other, whether related to this agreement or otherwise, and any claim or dispute related to this agreement shall be first
taken to mediation. If mediation efforts prove unsuccessful, the parties dispute moves to Federal District Court of Florida. Any
award of the court may be entered as a judgment in any court of competent jurisdiction. Further, should either party, successor
or assign of either party bring leading proceedings in connection with this agreement the party or parties prevailing in such proceeding
shall be entitled to their reasonable attorney's fees and costs from the non-prevailing party in addition to any other such relief
as may be granted.

 

10.
Non-waiver: No failure or neglect of either party hereto in any instance to exercise any right, power or
privilege under this agreement or under applicable law shall constitute a waiver of any other right, power or privilege in any
other instance. All waivers by either party must be in wiring and signed by the party to be charged.

 

11.
Entire Agreement: This Agreement contains the entire agreement and understanding between the parties and supersedes
any prior or contemporaneous written or oral agreements, representations and warranties between them respecting the subject matter
of this Agreement. This Agreement may be amended only by a writing signed by Sub-Licensees and by a duly authorized representative
of the Sub-Licensor. If any term, provision, covenant or condition of this Agreement, or the application to any person, place or
circumstance, shall be held to be invalid, unenforceable or void, the remainder of this Agreement and such term, provision, covenant
or condition as applied to other persons, places and circumstances shall remain in full force and effect.

 

12.Confidentiality.

 

Sub-Licensees acknowledges that it may have
access to confidential information regarding the Sub-Licensor and its business. Sub-Licensees agrees that it will not, during or
subsequent to the term of this Agreement, divulge, furnish or make accessible to any person (other than with the written permission
of Licensor) any knowledge or information or plans of Sub-Licensor with respect to Sub-Licensor or its business, including, but
not by way of limitation, the products of the Sub-Licensor, whether in the concept or development stage, or being marketed by Sub-Licensor
on the effective date of this Agreement or during the term hereof. Sub-Licensees agrees that all aforementioned terms and conditions
additionally apply to Master Licensor, ScripsAmerica, Inc.

 

    	4

    	 

    

 

13.

Covenant Not To Compete.

During the term of this Agreement, Sub-Licensees
warrants, represents and agrees that it will not directly participate in the information developed for and by Sub-Licensor, and
will not compete directly with Sub-Licensor in Sub-Licensor 's primary industry or related fields in the United States Market.
Sub-Licensees reserves the right to import, market and distribute medicinal and health related products from other vendors into
the Canada market, as long as the products are not competing with products licensed by Sub-Licensor to Sub-Licensees.

 

By signing this agreement the parties acknowledges
they have read the entire agreement and fully understand the terms, conditions and obligations of this agreement.Exhibit 10.24

 

SETTLEMENT AGREEMENT AND FULL RELEASE OF
ALL CLAIMS

 

This Settlement Agreement and Full Release
of All Claims (“Settlement and Release”) is entered into as of January 31, 2014 (“Effective Date”) by
and between Lenco Mobile Inc., a Delaware corporation (“Lenco”), and Michael Levinsohn, an individual residing in
Bellevue, Washington(“Levinsohn”) with respect to the following facts:

 

A.     Levinsohn was
previously Chairman of the Board and Chief Executive Officer of Lenco until on or around December 27, 2011, at which time he continued
as Chairman of the Board but his executive title changed to Executive Chairman;

 

B.     Levinsohn continued
as Chairman of the Board and Executive Chairman until he resigned from his position as Executive Chairman on September 17, 2013,
at which time he ceased to be an employee of Lenco but continued as a director and Chairman of the Board;

 

C.     Levinsohn and Lenco
had signed a Separation Agreement on June 11, 2013 (the “Separation Agreement”) that contained certain terms and conditions
that were to have applied to his separation but the Separation Agreement was made void by its own terms and therefore none of
the term or conditions therein are or were of any force or effect;

 

D.     Levinsohn and Lenco had entered into an
Executive Employment Agreement dated as of September 1, 2009 (the “Employment Agreement”) that expired by its own terms
on December 31, 2012;

 

E.     Lenco and 121 Mobile Solutions Inc., a
corporation wholly owned by Levinsohn, had entered into that certain Referral Agreement dated as of October 4, 2013 (the “Referral
Agreement”);

 

F.     Lenco issued to Levinsohn a stock option
grant (the “Grant”) on April 11, 2012 with respect to 6,500,000 shares of Lenco common stock (the “Option Shares”);

 

G.     Levinsohn and Lenco wish to enter into
this Settlement and Release to acknowledge Levinsohn’s resignation from the Board of Directors and provide a full and complete
release of any and all claims that Levinsohn or Lenco may have against each other. 121 Mobile Solutions Inc. has also signed below
to acknowledge the termination of the Referral Agreement and the release provisions applicable to 121 Mobile Solutions Inc. set
forth herein.

 

    	1

    	 

    

 

NOW, THEREFORE, the parties agree as follows:

 

1.     Resignation. Levinsohn has delivered
to Lenco a notice that Levinsohn has resigned from his position as a director and Chairman of the Lenco Board of Directors.

 

2.     Settlement Consideration. Lenco
will pay Levinsohn Twenty Thousand Dollars ($20,000) on the Release Effective Date. Lenco will pay on Levinsohn’s behalf
COBRA continuation premiums for health insurance coverage continuing through June 30, 2015 of the type generally available to Lenco
executives; provided that Levinsohn files for COBRA continuation coverage and takes such actions and signs and delivers such documents
as are necessary to continue such coverage.

 

3.     Termination of Referral Agreement;
Release. Levinsohn, Lenco and 121 Mobile Solutions Inc. agree that the Referral Agreement is hereby terminated and is of no
force and effect. All parties hereby waive and release any claims that any of them may have under the Referral Agreement.

 

4.     Other Agreements; Option Grants.

 

(a)     Levinsohn expressly acknowledges his post-employment
obligations under the Employment Agreement and all other agreements between Levinsohn and Lenco, including, without limitation,
any agreements regarding confidentiality, inventions and other intellectual property assignments or transfers, stock option agreements
and indemnification agreements (collectively, the "Other Agreements"), all of which obligations shall remain in full
force and effect.

 

(b)     With respect to option grants awarded to
Levinsohn, the terms of such option grants shall continue to govern the vesting, exercise and expiration of those option grants;
provided that with respect to the Grant, all of the Option Shares subject to the Grant shall be deemed to have vested on the Release
Effective Date and shall continue to be exercisable until April 11, 2022.

 

5.     Release of Claims 

 

5.1     By Levinsohn. Effective
as of the Release Effective Date:

 

(a)     Levinsohn, for himself and his beneficiaries,
estate, successors and assigns, fully and forever releases and discharges Lenco together with all parents, subsidiaries, affiliates,
related entities, fiduciaries, predecessors, successors, officers, directors, shareholders, agents, employees, investors and representatives
(collectively, “Releasees”) with respect to any and all claims, liabilities and causes of action, of every nature,
kind and description, in law, equity or otherwise, which have arisen, occurred or existed at any time prior to the signing of this
Settlement and Release, including, without limitation, any and all claims, liabilities and causes of action arising out of or relating
to Levinsohn’s employment with any Releasees, any prior employment agreement between Levinsohn and any Releasees and any
prior separation agreement between Levinsohn and any Releasees.

 

    	2

    	 

    

 

(b)     Levinsohn expressly waives any claims
against any Releasees and releases Releasees from any claims, whether known or unknown, which existed or may have existed at any
time up to the date of Levinsohn's execution of this Settlement and Release, including claims related in any way to Levinsohn's
employment with any Releasees or the ending of that relationship. This waiver and release includes, but is not limited to, any
claims for wages, bonuses, employment benefits, stock options or restricted stock, or damages of any kind whatsoever, arising out
of any common law torts, arising out of any contracts, express or implied, any covenant of good faith and fair dealing, express
or implied, any theory of wrongful discharge, any theory of negligence, any theory of retaliation, any theory of discrimination
or harassment in any form, any legal restriction on any Releasee's right to terminate employees, or any federal, state, or other
governmental statute, executive order, or ordinance, including, without limitation, Title VII of the Civil Rights Act of 1964 as
amended, the Civil Rights Act of 1991, the Civil Rights Act of 1866, 42 U.S.C. § 1981, the Americans with Disabilities
Act, the Age Discrimination in Employment Act, the Older Workers Benefit Protection Act, the Family and Medical Leave Act, the
Employee Retirement Income Security Act, the Unruh Civil Rights Act, the California Fair Employment and Housing Act, or any other
legal limitation on or regulation of the employment relationship.

 

(c)     This waiver and release by Levinsohn
is intended to be construed as broadly and comprehensively as the law permits. However, this waiver and release shall not be construed
as waiving or releasing any claim that as a matter of law cannot be waived or released.

 

(d)     Levinsohn and Releasees intend this Settlement
and Release to be a general release which shall bar to each and every claim, demand, or cause of action released in the Settlement
and Release. Levinsohn recognizes that he may have some claim, demand, or cause of action against Releasees of which Levinsohn
is completely unaware and unsuspecting or about which Levinsohn has limited information. Levinsohn understands and intends, in
executing this Settlement and Release, that the Settlement and Release will deprive Levinsohn of each such claim, demand or cause
of action and prevent Levinsohn from asserting it against Releasees, even if Levinsohn later learns information that might have
affected Levinsohn’s decision to enter into this Settlement and Release. In furtherance of this intention, Levinsohn expressly
waives any rights or benefits conferred by the provisions of section 1542 of the Civil Code of the State of California, or any
similar state law, which provides as follows:

 

A general release does not extend to claims which
the creditor does not know or suspect to exist in his or her favor at the time of executing the release, which if known by him
or her must have materially affected his or her settlement with the debtor.

 

    	3

    	 

    

 

(e)     Levinsohn represents that Levinsohn has
not filed any complaints, charges or lawsuits against Lenco with any governmental agency or any court, and agrees that Levinsohn
will not initiate any complaints or lawsuits in the future. Levinsohn does not hereby waive his right to file a charge with the
Equal Employment Opportunity Commission (“EEOC”) of similar government agency, but Levinsohn does hereby waive his
right to recover monetary relief as the result of any EEOC or other charge or complaint.

 

(f)     Levinsohn represents and warrants that
he is the sole owner of the actual or alleged claims, rights, causes of action, and other matters which are released herein, that
the same have not been assigned, transferred, or disposed of in fact, by operation of law, or in any manner, and that he has the
full right and power to grant, execute and deliver the releases, undertakings, and agreements contained herein.

 

(g)     The foregoing waivers and releases in
this Section 5 shall not preclude Levinsohn from pursuing claims relating to enforcing Levinsohn’s rights under this Settlement
and Release. Notwithstanding the foregoing, nothing in this Agreement shall be deemed to constitute a waiver or release of Levinsohn's
rights to indemnification for acts occurring prior to the Effective Date pursuant to the terms of the Indemnification Agreement
between Lenco and Levinsohn dated as of March 13, 2012 (the “Indemnification Agreement”), and Levinsohn’s statutory
indemnity rights.

 

5.2     By Lenco. Effective as of the
Release Effective Date:

 

(a)     Lenco, on its behalf and on behalf of
the Releasees, fully and forever releases and discharges Levinsohn with respect to any and all claims, liabilities and causes of
action, of every nature, kind and description, in law, equity or otherwise, which have arisen, occurred or existed at any time
prior to the signing of this Settlement and Release, including, without limitation, any and all claims, liabilities and causes
of action arising out of or relating to Levinsohn's employment with Lenco prior to the date of this Settlement and Release, any
prior employment agreement between the two parties and any prior separation agreement between the two parties.

 

(b)     Lenco expressly waives any claims against
Levinsohn, whether known or unknown, which existed or may have existed at any time up to the date of execution of this Settlement
and Release, including claims related in any way to Levinsohn's employment with Lenco or the ending of that relationship. This
waiver and release includes, but is not limited to damages of any kind whatsoever, arising out of any common law torts, arising
out of any contracts, express or implied, any covenant of good faith and fair dealing, express or implied, any theory of negligence,
any theory of retaliation, any theory of discrimination or harassment in any form, any governmental statute, executive order, or
ordinance, or any other legal limitation on or regulation of the employment relationship.

 

    	4

    	 

    

 

(c)     This waiver and release by Lenco is intended
to be construed as broadly and comprehensively as the law permits. However, this waiver and release shall not be construed as waiving
or releasing any claim that as a matter of law cannot be waived or released.

 

(d)     Lenco intends this Settlement and Release
to be a general release which shall bar to each and every claim, demand, or cause of action released in the Settlement and Release.
Lenco expressly recognizes that Releasees may have some claim, demand, or cause of action against Levinsohn, of which Lenco and
the Releasees, are completely unaware and unsuspecting or about which they have limited information. Lenco understands and intends,
in executing this Settlement and Release, that the Settlement and Release will deprive Lenco and the Releasees of each such claim,
demand or cause of action and prevent Lenco and the Releasees from asserting such claims against Levinsohn, even if Lenco or the
Releasees later learns information that might have affected Lenco’s decision to enter into this Settlement and Release. In
furtherance of this intention, Lenco expressly waives any rights or benefits conferred by the provisions of section 1542 of the
Civil Code of the State of California, or any similar state law, which provides as follows:

 

A general release does not extend to claims which
the creditor does not know or suspect to exist in his or her favor at the time of executing the release, which if known by him
or her must have materially affected his or her settlement with the debtor.

 

(e)     Lenco represents that it has not filed
any complaints, charges or lawsuits against Levinsohn with any governmental agency or any court, and agrees that it will not initiate
any complaints or lawsuits against Levinsohn in the future. Lenco undertakes that it will not provide any third party with information
relating to Levinsohn’s employment with Lenco except as done in the ordinary course of business or as required by law.

 

(f)     Lenco represents and warrants that it
is the sole owner of the actual or alleged claims, rights, causes of action, and other matters of Lenco which are released herein,
that the same have not been assigned, transferred, or disposed of in fact, by operation of law, or in any manner, and that Lenco
has the full right and power to grant, execute and deliver the releases, undertakings, and agreements contained herein on behalf
of Lenco.

 

(g)     The foregoing waivers and releases in
this Section 5.2 shall not apply in the event of any breach by Levinsohn of any of the representations or warranties set forth
in this Settlement Agreement and shall not preclude Lenco from pursuing claims or asserting defenses relating to enforcing its
rights under this Settlement and Release, under the Indemnification Agreement, under the terms of any option grant, or under any
terms of the Employment Agreement that according to the Employment Agreement survived termination thereof, including without limitation,
the provisions regarding assignment and ownership of intellectual property and confidentiality obligations.

 

    	5

    	 

    

 

6.     Nonsolicitation.

 

(a)     For one (1) year from the Release Effective
Date, Levinsohn will not induce, or attempt to induce, directly or indirectly, any employee, consultant, or independent contractor
of Lenco to leave such employment or relationship or to engage in, be employed by, perform services for, participate in or otherwise
be connected with, either directly or indirectly, me or any enterprise with which Levinsohn may in any way be associated.

 

(b)     For one (1) year from the Release Effective
Date, Levinsohn will not induce, or attempt to induce, directly or indirectly, any customer or prospective customer of Lenco to
do business with any person or entity that offers products or services that compete with products or services then offered by Lenco.
The foregoing prohibition regarding prospective customers shall apply to prospective customers that (i) as of the Effective Date,
Lenco has held discussions with regarding provision of products and/or services by Lenco, or (ii) Levinsohn knows or has reason
to know prior to Levinsohn contacting such customer that Lenco has held discussions with or has plans, appointments or meetings
set up to discuss with such customer the provision of products or services by Company. For purposes of this Section 6(b) a company
or business shall not be deemed to be a prospective customer of Lenco solely based on the fact that the company or business has
been identified by 121 Mobile Solutions Inc. as a prospect that 121 Mobile Solutions Inc. was pursuing.

 

7.     No Admission of Wrongdoing. This
Settlement and Release shall not be construed as an admission by either party of any wrongful or unlawful act or breach of contract.

 

8.     Nondisparagement. Levinsohn agrees
to refrain from making any derogatory or disparaging comments to the press or any individual or entity regarding Lenco, its business,
directors, employees, affiliates or related activities, or the relationship between the parties. Lenco agrees to refrain from making
any derogatory or disparaging comments to the press or any individual or entity regarding Levinsohn or the relationship between
the parties.

 

    	6

    	 

    

 

9.     Return of Property. Levinsohn confirms
that Levinsohn has returned to Lenco, or will return to Lenco within twenty-one (21) days of the Release Effective Date, all files,
memoranda, records, credit cards, pagers, computers, computer files, passwords and pass keys, card keys, or related physical or
electronic access devices, and any and all other property received from Lenco or any of its current or former employees or generated
by Levinsohn in the course of employment. Levinsohn shall be entitled to retain copies of information that relates to his financial
investment in Lenco.

 

10.     Levinsohn’s emails. Within
twenty-one (21) days of the Release Effective Date, Lenco will make a copy of the emails in the Inbox, Sent, Drafts and Archive
folders of Levinsohn’s Gmail account at email address michael.levinsohn@archermobile.com, michael.levinsohn@lencomobile.com,
or michael.levinsohn@helloarcher.com (the “Levinsohn Emails”) and then delete all of the Levinsohn Emails from the
account. Lenco will deposit the copy of the Levinsohn Emails with Perkins Coie and will delete any other copies of the Levinsohn
Emails from from Lenco’s servers, or any servers that Lenco controls, or are managed on Lenco’s behalf. Lenco will
not retrieve the Levinsohn Emails from Perkins Coie or use them for any purpose, other than (a) upon the order of any court or
administrative agency, (b) upon the request or demand of any regulatory agency or authority having jurisdiction over such party,
(c) to the extent compelled by legal process or required or requested pursuant to subpoena, interrogatories or other discovery
requests, and in each case only after notifying Levinsohn of the proposed retrieval and disclosure as far in advance of such disclosure
as is practically possible and after using reasonable efforts to ensure that any Levinsohn Emails so disclosed are accorded confidential
treatment, when and if available.

 

11.     Levinsohn’s Representations.
Levinsohn represents and warrants to Lenco that, to the best of his actual knowledge, during the time he was CEO of Lenco: (a)
all material financial transactions relating to Lenco’s operations were disclosed to Lenco’s chief financial officer
and independent auditors for review and inclusion in the financial statements filed by Lenco with the SEC; (b) Levinsohn did not
enter into any related party transaction with Lenco or any of its subsidiaries of a nature required to be disclosed under Item
404 of Regulation S-K, except as described in Lenco’s reports filed with the SEC; and (c) Levinsohn did not execute any agreement
to transfer any material interest in or ownership of the assets, technology or intellectual property used by Lenco or its subsidiaries
except as authorized by the Board of Directors or disclosed in Lenco’s reports filed with the SEC. 

 

12.     Press
Release. On or around the Release Effective Date, Lenco will issue a press release announcing his departure from the Board
of Directors in the form attached as Exhibit A.

 

    	7

    	 

    

 

13.     Severability. The provisions of
this Settlement and Release are severable, and if any part of it is found to be unlawful or unenforceable, the other provisions
of this Settlement and Release shall remain fully valid and enforceable to the maximum extent consistent with applicable law.

 

14.     Entire Agreement. This Settlement
and Release sets forth the entire understanding and agreement between Levinsohn and Lenco with respect to the subject matter hereof,
and supersedes any prior agreements or understandings, express or implied, pertaining to the terms of Levinsohn's employment with
Lenco, the employment relationship and/or the termination of the employment relationship and benefits to be provided in connection
therewith, except for the post-employment covenants of the Other Agreements. Each party acknowledges that in executing this Settlement
and Release, it is not relying upon any representation or statement by any representative of the other concerning the subject matter
of this Settlement and Release, except as expressly set forth in the text of the Settlement and Release. No modification or waiver
of this Settlement and Release will be effective unless evidenced in a writing signed by both parties.

 

15.     Governing Law; Venue; Fees and Costs.
This Settlement and Release will be governed by and construed exclusively in accordance with the laws of the State of Washington
without reference to its choice of law principles. The exclusive venue for any legal proceeding relating to this Settlement and
Release shall be in the state and federal courts located in King County, Washington, and each party irrevocably consents to the
jurisdiction of such courts for purposes of any such action. The prevailing party in any legal action relating to this Settlement
and Release shall be entitled to costs, expenses and reasonable attorneys' fees except as prohibited by applicable law.

 

16.     Knowing and Voluntary Agreement; Consideration
and Revocation Periods. Levinsohn agrees that Levinsohn has carefully read and fully understands all aspects of this Settlement
and Release, including the fact that this Settlement and Release releases any claims that Levinsohn might have against Lenco, including,
without limitation, claims under the federal Age Discrimination in Employment Act. Levinsohn agrees that Levinsohn has not relied
upon any representations or statements not set forth herein or made by Lenco's agents or representatives. Levinsohn is advised
to consult with an attorney prior to executing the Settlement and Release. Levinsohn has either done so or knowingly waived the
right to do so, and now enters into this Settlement and Release without duress or coercion from any source. Levinsohn agrees that
he has been provided the opportunity to consider for twenty-one (21) days whether to enter into this Settlement and Release, and
has voluntarily chosen to enter into it on this date. Levinsohn may revoke this Settlement and Release for a period of seven (7)
days following his execution of this Settlement and Release. The “Release Effective Date” of this Settlement and Release
shall be the day after the revocation period expires without revocation by Levinsohn. 

 

    	8

    	 

    

 

IN WITNESS WHEREOF, the parties have executed
this Settlement and Release as of the Effective Date.

 

 

/s/ Michael Levinsohn

Michael Levinsohn

 

 

Lenco Mobile, Inc.

 

/s/ Matthew Harris
 By:_________________________
 Title:________________________ 

 

Signed also, with respect to Paragraph 3, above by:

 

121 Mobile Solutions Inc.

 

 

/s/ Michael Levinsohn

By:________________________

Title:_______________________

 

 

 

 

    	9

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00229-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00229-of-00352.parquet"}]]